10xゲノミクスはQ32025での収益の期待に打ち勝ち,Q4ガイドを昇格し,株式が13.1%上昇した. 10x Genomics beat earnings expectations in Q3 2025, raised Q4 guidance, and saw stock rise 13.1%.

10x Genomicsは2025年第3四半期の収益を149百万ドルの収益で報告した.これは前年比わずかに減少したが,予想を4.6%上回った. 10x Genomics reported Q3 2025 earnings with revenue of $149 million, slightly down year-over-year but exceeding expectations by 4.6%. 同社は1株当たり0.22ドルの損失を公示し,同社の推定では22.3%の減少を報告した. The company posted a GAAP loss of $0.22 per share, beating estimates by 22.3%. 2025年第4四半期の収益予測を15600万ドルに上げ,需要の強化を示し,営業利益の改善を報告した. It raised its Q4 2025 revenue guidance to $156 million, signaling stronger demand, and reported improved operating margins. 株式は発売後13.1%上昇し,そのコア生命科学部におけるより優れた成果と回復の兆しに駆り立てられている. The stock rose 13.1% after the release, driven by better-than-expected results and signs of recovery in its core life sciences segments.